Publications by authors named "Edith Schermer"

Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or single-chain Env designs can be expressed as native-like trimers, undesired monomers, dimers and malformed trimers that elicit non-neutralizing antibodies are also formed, implying that these designs could benefit from further modifications for gene-based vaccination approaches. Here, we describe the triple tandem trimer (TTT) design, in which three Env protomers are genetically linked in a single open reading frame and express as native-like trimers.

View Article and Find Full Text PDF

Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its use has been restricted by the potential for local or global structural distortion. This is of particular importance when the protein in question requires a high degree of structural conservation for inducing a biological outcome such as the elicitation of antibodies to conformationally sensitive epitopes. The HIV-1 envelope glycoprotein (Env) trimer is metastable and shifts between different conformational states, complicating its use as a vaccine antigen.

View Article and Find Full Text PDF

For five health-related lifestyle factors (physical activity, weight, smoking, sleep, and alcohol consumption) we describe both population trends and individual changes over a period of 30 years in the same adult population. Dichotomous indicators (healthy/unhealthy) of lifestyle were analyzed for 3,139 participants measured every 5 years in the Doetinchem Cohort Study (1987-2017). Population trends over 30 years in physical inactivity and "unhealthy" alcohol consumption were flat (i.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers focused on enhancing the thermostability of HIV-1 Env immunogens to boost the effectiveness of candidate vaccines aimed at generating broadly neutralizing antibodies.
  • They developed a new version, BG505 SOSIP.v9 trimers, which showed significantly improved thermostability and reduced reactivity with non-neutralizing antibodies, achieving a melting temperature of 91.3°C.
  • The study demonstrated that higher stability of these trimers correlates with stronger and more consistent neutralizing antibody responses, and masking certain epitopes with glycans can redirect immune responses without sacrificing effectiveness.
View Article and Find Full Text PDF

The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glycosylated, creating a dense glycan shield that protects the underlying peptidic surface from antibody recognition. The absence of conserved glycans, due to missing potential N-linked glycosylation sites (PNGS), can result in strain-specific, autologous neutralizing antibody (NAb) responses. Here, we sought to gain a deeper understanding of the autologous neutralization by introducing holes in the otherwise dense glycan shields of the AMC011 and AMC016 SOSIP trimers.

View Article and Find Full Text PDF

The immunogenicity of HIV-1 envelope (Env) trimers is generally poor. We used the clinically relevant ConM SOSIP trimer to compare the ability of different adjuvants (squalene emulsion, ISCOMATRIX, GLA-LSQ, and MPLA liposomes) to support neutralizing antibody (NAb) responses in rabbits. The trimers were administered as free proteins or on nanoparticles.

View Article and Find Full Text PDF

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein.

View Article and Find Full Text PDF

Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied the therapeutic potency and escape pathways of bnAb PGDM1400 during monovalent therapy in human immune system (HIS) mice using the BG505, REJO, MJ4 and AMC008 virus isolates.

View Article and Find Full Text PDF

The induction of broadly neutralizing antibodies (bNAbs) is a major goal in vaccine research. HIV-1-infected individuals that develop exceptionally strong bNAb responses, termed elite neutralizers, can inform vaccine design by providing blueprints for the induction of similar bNAb responses. We describe a new recombinant native-like envelope glycoprotein (Env) SOSIP trimer, termed AMC009, based on the viral founder sequences of an elite neutralizer.

View Article and Find Full Text PDF

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein.

View Article and Find Full Text PDF
Article Synopsis
  • Stabilized HIV-1 envelope glycoproteins (Env) resembling the native form are being developed for vaccines to induce broadly neutralizing antibodies (bNAbs).
  • A new SOSIP trimer was created using a consensus sequence of all HIV-1 group M isolates, showcasing most known bNAb epitopes and some germline precursor ones.
  • The ConM trimer has shown to provoke strong neutralizing antibody (NAb) responses in animals, especially when delivered using ferritin nanoparticles, suggesting that consensus-based immunogens could aid in designing effective HIV-1 vaccines.
View Article and Find Full Text PDF

Broadly neutralizing antibodies (bNAbs) such as PGDM1400 show promise as prophylactic and therapeutic agents against HIV-1. Human immune system mice were passively immunized with different doses of PGDM1400 and challenged 24 h later with a high dose of HIV-1. We found that PGDM1400 provided protection against HIV-1 challenge in a concentration dependent manner and that the protective concentration in blood was ∼75-fold higher than the in vitro 50% inhibitory concentration.

View Article and Find Full Text PDF

Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for inducing broadly neutralizing antibodies (bNAbs) by vaccination. To date, these and alternative designs of native-like trimers, given singly or in pairs, have not induced bNAbs in test animals such as rabbits or macaques. Here, we have evaluated whether trivalent and tetravalent combinations of SOSIP trimers from clades A, B, and C, delivered simultaneously or sequentially, induce better neutralizing antibody responses in rabbits than when given alone.

View Article and Find Full Text PDF
Article Synopsis
  • A successful HIV-1 vaccine requires the creation of broadly neutralizing antibodies to target the HIV-1 envelope glycoprotein (Env), specifically its spike structure.
  • Researchers have developed modified Env trimers (like SOSIP.v5.2) that stabilize the spike and limit unwanted immune responses from non-neutralizing antibodies (non-NAbs), particularly from the V3 loop.
  • The new trimers show promise in reducing V3 non-NAbs in animal studies while maintaining the effective production of neutralizing antibodies, suggesting potential improvements in HIV vaccine strategies.
View Article and Find Full Text PDF
Article Synopsis
  • Engineers developed a stable and native-like version of the HIV-1 envelope glycoprotein trimer (BG505 SOSIP.664) to improve its use in vaccines.
  • Introducing new disulfide bonds between components of the glycoprotein enhances stability and reduces flexibility, which maintains its structure for better immune response.
  • The advanced SOSIP.v5 trimers showed strong antibody responses in rabbits, while SOSIP.v6 achieved some responses against different viruses, indicating potential for broad spectrum vaccine strategies.
View Article and Find Full Text PDF

Objective: Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the fibrillin-1 gene. Patients with MFS are at risk of aortic aneurysm formation and dissection. Usually, blood pressure-lowering drugs are used to reduce aortic events; however, this is not sufficient for most patients.

View Article and Find Full Text PDF